

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E24/20 - Hormones 2

Deadline: 20.10.2020

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability											
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}
(193) Ferritin					24						21	20	95%
Samples and groups	[µg/L]												
Sample A		367	76	21	24						21	21	100%
Other					24	0					21		
							4x 4/1, 4x 4/12, 4x 4/60, 3x 4/149, 3x 4/179, 1x 6/1, 2x 6/58, 1x 6/60, 1x 6/177, 1x 6/178						
Sample B		89,7	19	21	24						21	20	95%
Other					24	0					21		
							4x 4/1, 4x 4/12, 4x 4/60, 3x 4/149, 3x 4/179, 1x 6/1, 2x 6/58, 1x 6/60, 1x 6/177, 1x 6/178						
(320) LH					19						19	19	100%
Samples and groups	[U/L]												
Sample A		13,4	2,5	19	19						19	19	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		10,9	1,3	12	6	0	CVPG	11,1	0,20	15%	9,43	12,8	6
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		15,5	0,33	2,2	5	0	CVPG	15,8	0,10	15%	13,4	18,2	5
Other					8	0							8
								1x 3/25, 3x 4/1, 1x 4/29, 2x 4/149, 1x 4/179					
Sample B		69,5	12	18	19						19	19	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		57,2	5,2	9,1	6	0	CVPG	59,5	1,1	15%	50,5	68,5	6
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		76,5	1,7	2,2	5	0	CVPG	76,4	0,46	15%	64,9	87,9	5
Other					8	0							8
								1x 3/25, 3x 4/1, 1x 4/29, 2x 4/149, 1x 4/179					
(321) FSH					19						19	18	95%
Samples and groups	[U/L]												
Sample A		9,95	1,0	10	19						19	18	95%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		9,94	0,83	8,4	6	0	CVPG	10,1	0,22	15%	8,58	11,7	6
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		10,1	0,84	8,3	5	0	CVPG	9,8	0,058	15%	8,33	11,3	5
Other					8	0							8
								1x 3/25, 3x 4/1, 1x 4/29, 2x 4/149, 1x 4/179					
Sample B		33,6	2,8	8,2	19						19	18	95%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		32,7	2,2	6,8	6	0	CVPG	33	0,58	15%	28	38	6
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		35,3	2,4	6,7	5	0	CVPG	34,3	0,23	15%	29,1	39,5	5
Other					8	0							8
								1x 3/25, 3x 4/1, 1x 4/29, 2x 4/149, 1x 4/179					
(322) Prolactin					20						17	16	94%
Samples and groups	[mU/L]												
Sample A		725	61	8,4	20						17	17	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		692	29	4,2	7	0	CVPG	670	13	16%	562	778	7
Other					13	0							10
								1x 3/24, 1x 3/25, 1x 4/1, 2x 4/29, 4x 4/60, 2x 4/149, 2x 4/179					
Sample B		159	22	14	20						17	16	94%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		155	5,0	3,3	7	0	CVPG	155	2,8	16%	130	180	7
Other					13	0							10
								1x 3/24, 1x 3/25, 1x 4/1, 2x 4/29, 4x 4/60, 2x 4/149, 2x 4/179					
(325) Insulin					9						8	8	100%
Samples and groups	[mU/L]												
Sample A		96,5	17	18	9						8	8	100%
Other					9	0					8		
								1x 1/36, 3x 4/1, 1x 4/12, 2x 4/60, 2x 4/179					
Sample B		20,4	3,7	18	9						8	8	100%
Other					9	0					8		
								1x 1/36, 3x 4/1, 1x 4/12, 2x 4/60, 2x 4/179					
(326) Folate					22						22	18	82%
Samples and groups	[nmol/L]												
Sample A		27,0	6,6	24	22						22	21	95%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		31,9	1,2	3,6	5	0	CVPG	30,8	0,53	27%	22,4	39,2	5
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		24,6	1,5	6,3	8	0	CVPG	23,8	0,25	27%	17,3	30,3	8
Other					9	0							9
								3x 4/1, 3x 4/149, 3x 4/179					
Sample B		3,63	1,3	35	22						22	18	82%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		4,24	0,24	5,8	5	0	CVPG	3,73	0,15	±1,35	2,38	5,08	5

Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Slovakia, minimal size of the groups n = 5

EQA round: E24/20 - Hormones 2

Deadline: 20.10.2020

Test	[unit]						Comparability						N _{eva}	N _{suc}	S _{rel}	
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL					
(326) Folate																
Samples and groups	[nmol/L]				22								22	18	82%	
Sample B		3,63	1,3	35	22								22	18	82%	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		3,69	1,3	36	8	0	CVPG	3,16	0,11	±1,35	1,81	4,51	8			
Other					9	0							9			
								3x 4/1, 3x 4/149, 3x 4/179								
(327) Vitamin B12																
Samples and groups	[pmol/L]				22								22	20	91%	
Sample A		641	87	14	22								22	21	95%	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		535	32	5,9	5	0	CVPG	517	10	20%	413	621	5			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		674	64	9,4	8	0	CVPG	673	3,7	20%	538	808	8			
Other					9	0							9			
								3x 4/1, 3x 4/149, 3x 4/179								
Sample B		247	55	22	22								22	21	95%	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		177	5,6	3,1	5	0	CVPG	176	3,3	20%	140	212	5			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		288	22	7,6	8	0	CVPG	272	2,5	20%	217	327	8			
Other					9	0							9			
								3x 4/1, 3x 4/149, 3x 4/179								
(319) Vitamin B12 (active)																
Samples and groups	[pmol/L]				5								5	4	80%	
Sample A		203	79	39	5		CVP	245	47	asym.	120	600	5	5	100%	
Other					5	0							5			
								2x 4/1, 3x 4/60								
Sample B		69,2	4,1	5,9	5								5	4	80%	
Other					5	0							5			
								2x 4/1, 3x 4/60								
(328) hGH																
Samples and groups	[mU/L]				9								9	9	100%	
Sample A		29,0	2,8	9,7	9								9	9	100%	
Other					9	0							9			
								1x 1/36, 3x 4/12, 4x 4/29, 1x 4/60								
Sample B		10,8	1,2	11	9								9	9	100%	
Other					9	0							9			
								1x 1/36, 3x 4/12, 4x 4/29, 1x 4/60								
(329) IGF-1																
Samples and groups	[µg/L]				5								5	5	100%	
Sample A		447	8,2	1,8	5								5	5	100%	
Other					5	0							5			
								1x 1/36, 4x 4/29								
Sample B		167	4,4	2,7	5								5	5	100%	
Other					5	0							5			
								1x 1/36, 4x 4/29								
(390) Renin																
Samples and groups	[ng/L]				4								4	4	100%	
Sample A		35,9	11	31	4								4	4	100%	
Other					4	0							4			
								1x 1/185, 2x 2/66, 1x 4/164								
Sample B		34,0	15	46	4								4	4	100%	
Other					4	0							4			
								1x 1/185, 2x 2/66, 1x 4/164								
(392) IGF-BP3																
Samples and groups	[µg/L]				2								1	1	100%	
Sample A		3150	1100	33	2								1	1	100%	
Other					2	0							1			
								1x 1/183, 1x 4/29								
Sample B		3110	1000	32	2								1	1	100%	
Other					2	0							1			
								1x 1/183, 1x 4/29								
(393) C-peptide																
Samples and groups	[pmol/L]				13								12	12	100%	
Sample A		248	56	23	13								12	12	100%	
Other					13	0							12			
								1x 1/36, 3x 4/1, 2x 4/29, 4x 4/60, 3x 4/179								
Sample B		249	56	22	13								12	12	100%	
Other					13	0							12			
								1x 1/36, 3x 4/1, 2x 4/29, 4x 4/60, 3x 4/179								
(394) SHBG																
Samples and groups	[nmol/L]				10								10	9	90%	
Sample A		32,3	3,6	11	10								10	9	90%	
Other					10	0							10			
								2x 4/1, 1x 4/12, 2x 4/29, 3x 4/60, 2x 4/179								

